California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BOSTON, March 02, 2016 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will host a conference call on Wednesday, March 9, 2016 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and the full year ended December 31, 2015.
Participants may access the call by dialing (973) 500-2177 in the U.S. or (844) 824-7428 outside the U.S. and referencing conference ID number 59462061. The call will also be webcast live on the Company's website at http://ir.zafgen.com/events.cfm. A replay of this conference call will be available beginning at 7:30 p.m. ET on March 9, 2016 through March 23, 2016 by dialing (404) 537-3406 in the U.S. or (855) 859-2056 outside the U.S. To access the replay please provide Conference ID number 59462061.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 [email protected] [email protected]
